Holen Sie sich die Stockscreener-App
78.76
1.86%
1.2822
Schlusskurs vom Vortag:
$77.48
Offen:
$78.5
24-Stunden-Volumen:
47,655
Relative Volume:
0.05
Marktkapitalisierung:
$5.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-28.60
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
+4.14%
1M Leistung:
+5.59%
6M Leistung:
+113.18%
1J Leistung:
+60.37%
1-Tages-Spanne:
$77.80
$80.24
1-Wochen-Bereich:
$72.56
$80.34
52-Wochen-Spanne:
$26.20
$80.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie APGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.76 | 5.29B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.19 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.84 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.19 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Can Apogee Therapeutics Inc. stock weather global recessionJuly 2025 Summary & Verified Technical Trade Signals - ulpravda.ru
Levels Update: How Apogee Therapeutics Inc. stock reacts to job market data2025 Market Trends & Fast Gaining Stock Strategy Reports - ulpravda.ru
Apogee Therapeutics (APGE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
What insider trading reveals about Apogee Therapeutics Inc. stock2025 Winners & Losers & Verified Momentum Stock Alerts - ulpravda.ru
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com South Africa
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation - Nasdaq
Will Apogee Therapeutics Inc. stock gain from lower inflationMarket Profile Overview & High Yield Portfolio Picks - ulpravda.ru
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data - Investing.com Nigeria
March 20th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
Will Apogee Therapeutics Inc. stock benefit from AI adoptionBreakout Stock Watch & Secret Picks Wall Street Isn’t Talking About - ulpravda.ru
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Apogee Therapeutics CFO Sells 8,000 Shares - TradingView — Track All Markets
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating - Investing.com Nigeria
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data By Investing.com - Investing.com South Africa
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com Nigeria
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com India
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics to report interim asthma trial results By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Interim Results for Zumilokibart (APG777) in Mild-to-Moderate Asthma and Highlights 2026 Development Milestones - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - GlobeNewswire Inc.
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - Sahm
Apogee Therapeutics to report interim asthma trial results - Investing.com India
User - FinancialContent
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00 - MarketBeat
(APGE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis Report | Financials & Insights - Benzinga
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Apogee Therapeutics Earnings Notes - Trefis
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com Australia
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
Apogee Therapeutics stock hits all-time high of 78.19 USD - Investing.com
Apogee Therapeutics stock hits all-time high of 78.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighWhat's Next? - MarketBeat
Is Apogee Therapeutics Inc. stock a safe investment in uncertain markets2025 Winners & Losers & Safe Capital Growth Tips - DonanımHaber
Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat
Market Outlook: Will Apogee Therapeutics Inc. stock benefit from AI adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):